Xuejun Chen

This paper develops a nanoparticle-based junctional vaccine targeting PfCSP and compares its efficacy to the R21 vaccine in reducing malaria liver burden in mice.

This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.